Anterior gradient 2: a novel player in tumor cell biology.

Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216224%3A14110%2F11%3A00052918" target="_blank" >RIV/00216224:14110/11:00052918 - isvavai.cz</a>
Alternative codes found
RIV/00209805:_____/11:#0000146
Result on the web
<a href="http://dx.doi.org/10.1016/j.canlet.2010.12.023" target="_blank" >http://dx.doi.org/10.1016/j.canlet.2010.12.023</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1016/j.canlet.2010.12.023" target="_blank" >10.1016/j.canlet.2010.12.023</a>

Result language
angličtina
Original language name
Anterior gradient 2: a novel player in tumor cell biology.
Original language description
AGR2 has evolutionarily conserved roles in development and tissue regeneration and is linked with several human cancers. The exact functions and regulation of AGR2 are poorly understood, but current data identify AGR2 as a clinically relevant factor thatmodulates the behavior and response of hormone-dependent cancers (breast, prostate) and hormone-independent cancers (colorectal, pancreatic, esophageal and other common cancers). AGR2 protein expression induces metastasis, acts as a p53 tumor suppressorinhibitor and survival factor, participates directly in neoplastic transformation and is involved in drug resistance. Thus, AGR2 is an important tumor biomarker and negative prognostic factor potentially exploitable in clinical practice.
Czech name
—
Czech description
—

Type
J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)
CEP classification
EB - Genetics and molecular biology
OECD FORD branch
—

Project
Result was created during the realization of more than one project. More information in the Projects tab.
Continuities
P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Publication year
2011
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Similar results(10)